DSM Nutritional Products was at the World Congress on Osteoarthritis in Rome
last week to present new research that demonstrates additional benefits for
their new joint health supplement, i-flex™ . The latest advantages of the
specially processed rosehip powder used in i-flex™ (and LitoZin™ for the
European market) have been demonstrated in a host of placebo controlled human
clinical studies over the past decade. The mechanism of action is considered
to be a combination of anti-inflammatory and anti-oxidative processes
attributable to the vitamins, carotenoids and galactolipids found in the
product. New studies conducted by DSM Nutritional Products have now gone a
stage further, demonstrating protective and even regenerative effects on human
cartilage cells in-vitro.
According to senior author Dr. Joseph Schwager: “Our studies
demonstrate that i-flex™ reduces catabolic processes (and thus
degeneration) in human cartilage cells and at the same time enhances anabolic
processes (i.e. regeneration).” Lead author Nathalie Richard adds: “
We also confirmed the anti-inflammatory effects of i-flex™ in different cell
populations that contribute to joint inflammation.” The new in-vitro data
provides additional evidence on the cellular and molecular level and
compliments the thorough body of published human clinical evidence of i-flex™
for positive effects on joint health.
The World Congress on Osteoarthritis is the leading scientific forum for
research on osteoarthritis and was attended by over 1,000 of the world's
leading scientists, clinicians, clinical investigators, rheumatologists,
orthopedists and radiologists. DSM will present the positive effects of
i-flex™ on human cartilage cells at another major forum for arthritis
research, the Congress of the Asia Pacific League of Associations for
Rheumatology, 23-27 September 2008, in Pacifico Yokohama, Japan.
About i-flex™
i-flex™ is backed by reliable scientific
data gathered from several international scientific studies involving more
than 400 participants. Studies have demonstrated that the unique rosehip
powder used in i-flex™ is able to soothe joints and improve flexibility and
mobility, with no known side effects. Over 80% of the participants in these
placebo-controlled studies reported joint health benefits, often in as little
as three weeks.
About DSM Nutritional Products
DSM Nutritional Products is the
world's leading supplier of vitamins, carotenoids and other fine chemicals to
the feed, food, pharmaceutical and personal care industries. The business has
sales of over EUR 2 billion and a long tradition as a pioneer in the discovery
of new products, new formulations and attractive applications for all industry
segments. For further company information please visit
www.dsmnutritionalproducts.com.
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and
Materials Sciences that contribute to the quality of life. DSM’s products and
services are used globally in a wide range of markets and applications,
supporting a healthier, more sustainable and more enjoyable way of life. End
markets include human and animal nutrition and health, personal care,
pharmaceuticals, automotive, coatings and paint, electrics and electronics,
life protection and housing. DSM has annual sales of almost EUR 8.8 billion
and employs some 23,000 people worldwide. The company is headquartered in the
Netherlands, with locations on five continents. DSM is listed on Euronext
Amsterdam. More information:
www.dsm.com.
i-flex™ is a registered trademark of Royal DSM N.V
Litozin™ is a
registered trademark of Axellus
For more information:
DSM Nutritional Products
Emma
Peyrachon
Tel. +41 (0)61 815 89 34
Fax +41 (0)61 815 88 90
E-mail: emma.peyrachon@dsm.com
Bill Brown - USA
Tel. +1 973 257 8288
Fax +1 973 257 8437
E-mail: william-j.brown@dsm.com
Forward-looking statements
This press release contains
forward-looking statements. These statements are based on current
expectations, estimates and projections of DSM and information currently
available to the company. The statements involve certain risks and
uncertainties that are difficult to predict and therefore DSM does not
guarantee that its expectations will be realized. Furthermore, DSM has no
obligation to update the statements contained in this press release. The
English language version of the press release is leading.
